{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:06:10Z","timestamp":1780481170500,"version":"3.54.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This study aims to assess different advanced treatments modalities in terms of their toxicity NTCPs and the induced second primary cancers excess absolute risk (EARs) using in-house software \u201cCOUPOLE\u201d in case of prostate cancer. A total of 72 patients (GI, GII, GIII, and GIV) were treated using: VMAT1, VMAT2, HT and 3D-CRT. The treatment was planned with 6 MV using VARIAN HDX 2100C, VERSA HD Linear Accelerator, TOMOTHERAPY and ELEKTA Synergy. The prescribed dose was 76\u00a0Gy\/2\u00a0Gy\/F for GI and GII and 71.3\u00a0Gy\/2.3\u00a0Gy\/F for GIII and GIV. The Normal Tissue Complication Probability NTCPs (%) results for rectum\u00a0=\u00a09.5, 7.1, 5.18, and 22.46 for GI, GII, GIII, and GIV. The NTCP (%) for bladder\u00a0=\u00a00.05 for GI; 0.041 for GII; 0.0 and 1.67 for GIII and GIV. The EAR (\/10000PY) for rectum and bladder are: 0.07(GII), 1.71(GIII), 1.60(GIV), and 6.30(GI), 0.01 (GII), 0.46(GIII), and 0.46(GIV), respectively. Minor toxicity for OARs when using HT but the risk is significant for bladder for HT and VMAT.<\/jats:p>","DOI":"10.1093\/rpd\/ncaf197","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T12:27:50Z","timestamp":1767011270000},"page":"713-719","source":"Crossref","is-referenced-by-count":0,"title":["Toxicity and risk after using new modalities of radiotherapy in Algeria: retrospective intercomparison study"],"prefix":"10.1093","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6915-3035","authenticated-orcid":false,"given":"Assya","family":"Boughalia","sequence":"first","affiliation":[{"name":"Atomic and Radiobiological Department, Physics Section, Nuclear Research Centre of Algiers , Algiers ,","place":["Algeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Fellah","sequence":"additional","affiliation":[{"name":"Physics Faculty, Houari Boumediene University Bab Ezzouar Algiers , Algiers , \u00a0","place":["Algeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zineddine","family":"El Ghribi","sequence":"additional","affiliation":[{"name":"Radiotherapy Oncology Department, Fatima El Azhar Centre Dely Ibrahim , Algiers ,","place":["Algeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siam","family":"Oukrif","sequence":"additional","affiliation":[{"name":"Radiotherapy Oncology Department, Centre Pierre et Marie Curie , Algiers ,","place":["Algeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"2026060305103701600_ref1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s12558-014-0342-9","article-title":"Cancers urologiques en Alg\u00e9rie : profil histo\u00e9pid\u00e9miologique \u00e0 propos de 348 cas","volume":"7","author":"Salah","year":"2015","journal-title":"Afr J Cancer"},{"key":"2026060305103701600_ref2","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","article-title":"The epigenomics of cancer","volume":"128","author":"Jones","year":"2007","journal-title":"Cell"},{"key":"2026060305103701600_ref3","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ijrobp.2008.04.063","article-title":"Role of intensity-modulated radiation-therapy in reducing toxicity in dose escalation for localized prostate cancer","volume":"73","author":"Al Mamgani","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026060305103701600_ref4","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.meddos.2010.05.001","article-title":"Treatment and dosimetric advantages between VMAT, IMRT, and helical tomotherapy in prostate cancer","volume":"36","author":"Tsai","year":"2011","journal-title":"Med Dosim"},{"key":"2026060305103701600_ref5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1259\/bjr\/84246820","article-title":"Clinical use of intensity-modulated radiation-therapy: part I","volume":"77","author":"Guerrero Urbano","year":"2004","journal-title":"Br J Radiol"},{"key":"2026060305103701600_ref6","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1093\/jnci\/djq346","article-title":"Cancer risks after radiation exposure in middle age","volume":"102","author":"Shuryak","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"2026060305103701600_ref7"},{"key":"2026060305103701600_ref8","year":"1999"},{"key":"2026060305103701600_ref9","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.2307\/3576626","article-title":"Complication probability as assessed from dose volume histograms","volume":"104","author":"Lyman","year":"1985","journal-title":"Radiat Res Suppl"},{"key":"2026060305103701600_ref10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1053\/srao.2001.23478","article-title":"Modeling the effect of inhomogeneous dose distributions in normal tissue","volume":"11","author":"Yorke","year":"2001","journal-title":"Semin Radiat Oncol"},{"key":"2026060305103701600_ref11","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/0360-3016(89)90972-3","article-title":"Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method","volume":"16","author":"Kutcher","year":"1989","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026060305103701600_ref12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00411-007-0151-y","article-title":"Cancer risk estimates from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy","volume":"47","author":"Schneider","year":"2004","journal-title":"Radiat Environ Biophys"},{"key":"2026060305103701600_ref13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-4682-8-27","article-title":"Site-specific dose-response relationships for cancer induction from the combined Japanese a-bomb and hodgkin cohorts for doses relevant to radiotherapy","volume":"8","author":"Schneider","year":"2011","journal-title":"Theor Biol Med Model"},{"key":"2026060305103701600_ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1667\/RR0763.1","article-title":"Solid cancer incidence in atomic bomb survivors :1958\u20131998","volume":"168","author":"Preston","year":"2007","journal-title":"Radiat Res"},{"key":"2026060305103701600_ref15","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ejmp.2017.02.015","article-title":"Models for the risk of secondary cancers from radiotherapy","volume":"42","author":"Dasu","year":"2017","journal-title":"Phys Med"},{"key":"2026060305103701600_ref16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ejmp.2017.07.003","article-title":"Radiobiological evaluation of prostate cancer IMRT and conformal -RTplans using different protocols","volume":"40","author":"Mavroidis","year":"2017","journal-title":"Phys Med"},{"key":"2026060305103701600_ref17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0360-3016(03)00073-7","article-title":"Radiation induced second cancers: the impact of 3D-CRT and IMRT","volume":"56","author":"Hall","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026060305103701600_ref18","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.ijrobp.2004.04.014","article-title":"Fractionation and late toxicity","volume":"60","author":"Brenner","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026060305103701600_ref19","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/02841860500401159","article-title":"Dose-effect models for risk-relationship to cell survival parameters","volume":"44","author":"Dasu","year":"2005","journal-title":"Acta Oncol"},{"key":"2026060305103701600_ref20","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/02841860510029833","article-title":"The use of risk estimation models for the induction of secondary cancers following radiation-therapy","volume":"44","author":"Dasu","year":"2004","journal-title":"Acta Oncol"}],"container-title":["Radiation Protection Dosimetry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rpd\/article-pdf\/202\/9\/713\/68458643\/ncaf197.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rpd\/article-pdf\/202\/9\/713\/68458643\/ncaf197.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:10:42Z","timestamp":1780477842000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rpd\/article\/202\/9\/713\/8700447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":20,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,6,3]]},"published-print":{"date-parts":[[2026,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/rpd\/ncaf197","relation":{},"ISSN":["0144-8420","1742-3406"],"issn-type":[{"value":"0144-8420","type":"print"},{"value":"1742-3406","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,6]]}}}